标准剂量肾上腺素与安慰剂在院外心脏骤停中的比较:系统评价与荟萃分析
该系统评价与荟萃分析纳入5项随机对照试验共17635例院外心脏骤停患者,比较标准剂量肾上腺素与安慰剂。肾上腺素组自主循环恢复(OR=3.10,95%CI 2.16-4.45)和入院存活(OR=2.52,95%CI 1.63-3.88)均高于安慰剂组,但出院存活(OR=1.09,95%CI 0.48-2.47)和神经功能结局(OR=0.81,95%CI 0.34-1.96)无显著差异。作者认为需进一步研究以控制住院期间管理中的混杂因素。
要点
- 院外心脏骤停中,标准剂量肾上腺素较安慰剂提高自主循环恢复率(OR=3.10,95%CI 2.16-4.45)。
- 肾上腺素较安慰剂提高入院存活率(OR=2.52,95%CI 1.63-3.88)。
- 肾上腺素与安慰剂相比未提高出院存活率(OR=1.09,95%CI 0.48-2.47)。
- 肾上腺素与安慰剂相比神经功能结局无显著差异(OR=0.81,95%CI 0.34-1.96)。
- 作者认为需进一步研究以控制住院期间管理中的混杂因素。
适用人群与场景
- 院外心脏骤停患者,纳入5项随机对照试验共17635例。
研究设计与关键结果
- 系统评价与荟萃分析,纳入5项随机对照试验,共17635例院外心脏骤停患者,比较标准剂量肾上腺素与安慰剂。
- 主要终点出院存活率:肾上腺素组与安慰剂组无显著差异(OR=1.09,95%CI 0.48-2.47,I²=77%,p=0.84)。
- 自主循环恢复:肾上腺素组高于安慰剂组(OR=3.10,95%CI 2.16-4.45,I²=74%,p<0.0001)。
- 入院存活率:肾上腺素组高于安慰剂组(OR=2.52,95%CI 1.63-3.88,I²=94%,p<0.0001)。
- 神经功能结局:肾上腺素组与安慰剂组无显著差异(OR=0.81,95%CI 0.34-1.96)。
- 3个月存活率:肾上腺素组与安慰剂组无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,仅纳入随机对照试验;所有研究均评估了证据等级和偏倚风险。
- 局限:异质性高(自主循环恢复I²=74%,入院存活I²=94%,出院存活I²=77%)。
- 局限:作者指出需进一步研究以控制住院期间管理中的混杂因素。
对床旁实践的改变
- 在院外心脏骤停中,使用标准剂量肾上腺素可能提高自主循环恢复和入院存活,但未显示提高出院存活、神经功能结局或3个月存活。
- 作者认为需进一步研究以控制住院期间管理中的混杂因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Out of hospital cardiac arrest (OHCA) is a time critical and heterogeneous presentation. The most appropriate management strategies remain an issue for debate. The aim of this systematic review and meta-analysis was to determine the association of epinephrine versus placebo with return of spontaneous circulation, survival to hospital admission, survival to hospital discharge and neurological outcomes in out of hospital cardiac arrest.
METHODS: A systematic review of five databases was performed from inception to August 2018. Only randomised controlled trials were considered eligible for inclusion. The primary outcome was survival to hospital discharge. Secondary outcomes were ROSC, survival to hospital admission, neurological function on discharge and three-month survival. All studies were assessed for level of evidence and risk of bias.
RESULTS: Five randomised controlled trials with 17,635 patients were identified for inclusion. Use of epinephrine was associated with increased ROSC (OR = 3.10; 95% CI = 2.16 to 4.45; I2 = 74%; p < 0.0001) and increased survival to hospital admission OR = 2.52; 95% CI = 1.63 to 3.88; I2 = 94%; p < 0.0001). However, epinephrine was not associated with increased survival to discharge (OR = 1.09; 95% CI = 0.48 to 2.47; I2 = 77%; p = 0.84) or differences in neurological outcomes (OR = 0.81; 95% CI = 0.34 to 1.96).
DISCUSSION: This study was a systematic review and meta-analysis of epinephrine versus placebo in OHCA. The use of epinephrine was associated with improved ROSC and survival to hospital admission. However, use of epinephrine was not associated with a significant difference in survival to hospital discharge, neurological outcomes or survival to 3 months. Further research is required to control for the confounders during inpatient management.
参考来源
- Kempton H, Vlok R, Thang C, et al. Standard dose epinephrine versus placebo in out of hospital cardiac arrest: A systematic review and meta-analysis. Am J Emerg Med. 2019. PMID: 30658877. doi:10.1016/j.ajem.2018.12.055
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。